London
· Delayed Price · Currency is GBP · Price in USD CRISPR Therapeutics AG Statistics
Total Valuation
LON:0VRQ has a market cap or net worth of GBP 3.25 billion. The enterprise value is 1.92 billion.
| Market Cap | 3.25B |
| Enterprise Value | 1.92B |
Important Dates
The last earnings date was Friday, February 21, 2025.
| Earnings Date | Feb 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +6.49% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 84.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.57 |
| EV / Sales | 65.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.63 |
Financial Position
The company has a current ratio of 22.07, with a Debt / Equity ratio of 0.12.
| Current Ratio | 22.07 |
| Quick Ratio | 22.00 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.55 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.20% and return on invested capital (ROIC) is -13.64%.
| Return on Equity (ROE) | -19.20% |
| Return on Assets (ROA) | -13.04% |
| Return on Invested Capital (ROIC) | -13.64% |
| Return on Capital Employed (ROCE) | -21.66% |
| Revenue Per Employee | 75,840 |
| Profits Per Employee | -744,405 |
| Employee Count | 393 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -39.27% |
| 50-Day Moving Average | 42.81 |
| 200-Day Moving Average | 49.45 |
| Relative Strength Index (RSI) | 56.66 |
| Average Volume (20 Days) | 9,565 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.94 |
Income Statement
In the last 12 months, LON:0VRQ had revenue of GBP 29.81 million and -292.55 million in losses. Loss per share was -3.47.
| Revenue | 29.81M |
| Gross Profit | -314.39M |
| Operating Income | -372.68M |
| Pretax Income | -289.69M |
| Net Income | -292.55M |
| EBITDA | -357.30M |
| EBIT | -372.68M |
| Loss Per Share | -3.47 |
Balance Sheet
The company has 1.52 billion in cash and 178.68 million in debt, giving a net cash position of 1.34 billion.
| Cash & Cash Equivalents | 1.52B |
| Total Debt | 178.68M |
| Net Cash | 1.34B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.54B |
| Book Value Per Share | 18.00 |
| Working Capital | 1.48B |
Cash Flow
In the last 12 months, operating cash flow was -114.04 million and capital expenditures -1.52 million, giving a free cash flow of -115.56 million.
| Operating Cash Flow | -114.04M |
| Capital Expenditures | -1.52M |
| Free Cash Flow | -115.56M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,250.38% |
| Pretax Margin | -971.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0VRQ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.49% |
| Shareholder Yield | -6.49% |
| Earnings Yield | -9.00% |
| FCF Yield | -3.55% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0VRQ has an Altman Z-Score of 8.7.
| Altman Z-Score | 8.7 |
| Piotroski F-Score | n/a |